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Abstract
Autophagy is a homeostatic mechanism of lysosomal degradation. Defective autophagy has been linked to various
disorders such as impaired control of pathogens and neurodegeneration. Autophagy is regulated by a complex array of
signaling pathways that act upstream of autophagy proteins. Little is known about the role of altered regulatory signaling in
disorders associated with defective autophagy. In particular, it is not known if pathogens inhibit autophagy by modulation
of upstream regulatory pathways. Cells infected with HIV-1 blocked rapamycin-induced autophagy and CD40-induced
autophagic killing of Toxoplasma gondii in bystander (non-HIV-1 infected) macrophage/monocytic cells. Blockade of
autophagy was dependent on Src-Akt and STAT3 triggered by HIV-1 Tat and IL-10. Neutralization of the upstream receptors
VEGFR, b-integrin or CXCR4, as well as of HIV-1 Tat or IL-10 restored autophagy in macrophage/monocytic cells exposed to
HIV-1-infected cells. Defective autophagic killing of T. gondii was detected in monocyte-derived macrophages from a subset
of HIV-1
+ patients. This defect was also reverted by neutralization of Tat or IL-10. These studies revealed that a pathogen can
impair autophagy in non-infected cells by activating counter-regulatory pathways. The fact that pharmacologic
manipulation of cell signaling restored autophagy in cells exposed to HIV-1-infected cells raises the possibility of
therapeutic manipulation of cell signaling to restore autophagy in HIV-1 infection.
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Introduction
Autophagy is a conserved degradative process whereby a double
membrane vesicle, an autophagosome, forms around a portion of the
cytoplasm or an organelle and fuses with a late endosome/lysosome
resulting in enzymatic degradation of its cargo [1,2]. Autophagy was
originallydescribed asa homeostatic mechanism that providesenergy
and substrates for synthesis of essential macromolecules during
starvation [1,2]. However, it is now recognized that autophagy is
involved in many other processes. Indeed, deficiency in autophagy
promotes disorders such as cancer, neurodegeneration, myopathy,
senescence and susceptibility to infections [3].
Autophagy can act as an innate anti-microbial mechanism
against several pathogens both in vitro [4,5,6] and in vivo [7,8,9,10].
Autophagy is also an important component of adaptive immunity
against pathogens. IFN-c or CD40 enables macrophages to kill
Mycobacterium tuberculosis or Toxoplasma gondii via autophagy,
respectively [4,11,12]. In addition, autophagy has been reported
to enhance antigen presentation [13,14]. In a model of
immunization with M. tuberculosis-infected dendritic cells, in vitro
treatment of these cells with a pharmacologic stimulator of
autophagy improved the efficacy of immunization [15].
Autophagy-related (Atg) proteins mediate the formation of
autophagosomes. In contrast to the highly conserved nature of Atg
proteins, the regulatory molecules that control autophagy are
varied, including JNK, ERK1/2, AMP kinase, class I and class III
PI3K, Akt, mTOR, JAK, STAT, eIF2a kinases, DAPK, Bcl-2
family proteins, the p53 tumor suppressor, ubiquitination, the ER-
membrane-associated protein, Ire-1 [16]. Little is known about the
role of these signaling pathways in diseases linked to dysregulation
of autophagy.
Questions that are receiving increased attention are whether and
how pathogens inhibit autophagy. Pathogens have been reported to
inhibit autophagy by expressing virulence factors that impair the
function of Atg proteins [6,8,17]. However, to our knowledge, there
is no demonstration of whether pathogens interfere with autophagy
by modulating upstream signaling mechanisms. Addressing this
question is key to attempts to modulate autophagy for therapeutic
purposes. While approaches that target Atg proteins are likely to
result in generalized, non-specific modulation of autophagy,
approaches aimed at preventing dysregulation of the pathways
upstream of autophagy are more likely to be of therapeutic benefit.
It has recently been reported that HIV-1 interacts with the
autophagy pathway in cells infected with the virus. Autophagy is
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the degradative stage of autophagy is prevented by the interaction
between viral protein Nef and the autophagy protein Beclin 1 [17].
One of the important aspects of the pathophysiology of HIV-1
infection is that despite the fact that most cells of the immune
system are not infected with the virus, HIV-1 can affect the
function of non-infected cells creating a more global effect to HIV-
1 infection. In this regard, cell-free supernatants from microglia
obtained from SIV-1-infected monkeys inhibit autophagy in
bystander neurons [19]. However, it was not determined if the
inhibition of autophagy is a direct consequence of SIV-1. Thus, it
is not known if HIV-1 inhibits autophagy in bystander cells, and if
this is the case, by what mechanisms such an inhibition occurs. We
uncovered that HIV-1 inhibits autophagy in bystander macro-
phage/monocytic cells by acting through counter-regulators of this
process, Src, Akt, and STAT3. This is the first evidence of a
pathogen targeting signals upstream of autophagy to impair this
process. These findings are likely relevant to key aspects of HIV-1-
induced disease since they may contribute to susceptibility to
infections and immune evasion by inhibition of antigen recogni-
tion as well as neuro-degeneration associated with HIV-1.
Importantly, we also report that it is possible to prevent HIV-1
from inhibiting autophagy by pharmacologic manipulation of cell
signaling.
Results
HIV-1 blocks autophagic killing of T. gondii in bystander
macrophages
CD40 stimulation of macrophages results in killing of T. gondii
through autophagy [11,12]. To determine whether autophagy is
affected by HIV-1, we examined autophagic killing of T. gondii in
macrophages from HIV-1
+ patients. Monocyte-derived macro-
phages (MDM) from HIV-1
+ patients and healthy controls were
incubated with or without CD154 (CD40 ligand) followed by
challenge with T. gondii. MDM from 5 of a total of 23 HIV-1
+
patients exhibited defective induction of anti-T. gondii activity
(Figure 1A). Impaired anti-T. gondii activity was reproducible since
similar results were obtained when MDM were retested 2 to 3
different times. The group of HIV-1
+ patients with defective
CD40-induced toxoplasmacidal response will be referred to as
CD40 non-responders. CD40-induced anti-T. gondii activity did
not correlate with CD4 counts or plasma viral load (R=0.02;
p=0.76; data not shown). Impaired CD40-dependent toxoplas-
macidal activity was not due to differences in CD40 expression on
MDM (CD40 corrected mean fluorescence intensity: controls
26.664.4; CD40 responders 29.964.5; CD40 non-responders
32.666.4; p.0.1). While CD40 induces T. gondii killing through
autophagy, IFN-c works independently of autophagy to kill T.
gondii [11]. Indeed, in marked contrast to results obtained with
CD40-stimulated MDM, anti-T. gondii activity induced by IFN-c
was similar in all groups (Figure 1B).
Replication-competent virus can be present in a small
percentage of peripheral blood monocytes from HIV-1
+ patients,
even in those receiving anti-retroviral therapy and with undetect-
able plasma viral load [20]. This raised the possibility that MDM
productively infected with HIV-1 may impair CD40-dependent
autophagic killing of T. gondii in MDM not infected with HIV-1.
To address this possibility, MDM from healthy controls were
infected with env-deficient, nef-deficient Heat Stable Antigen
(HSA)-encoding HIV-1. The virus was pseudotyped with VSV-
G envelope to enable initial infection. This pseudotyped HIV-1 is
competent for a single round of replication since it lacks expression
of gp160. Expression of HSA or intracellular p24 was used to
quantitate the percentage of macrophages infected with pseudo-
typed HIV-1. Uninfected MDM incubated with pseudotyped
HIV-1-infected MDM were unable to acquire anti-T. gondii
activity in response to CD40 stimulation (Figure 1C). This
inhibitory effect took place even when a low percentage of the
total MDM population was infected with HIV-1 (Figure 1D). To
determine if the inhibition of anti-microbial activity required the
expression of HIV-1 genes we treated cultures with the nucleoside
analog reverse transcriptase inhibitor, zidovudine. Addition of
zidovudine (AZT) 2 h after incubation with HIV-1, prevented
expression of HIV-1 genes in MDM as assessed by intracellular
p24 (not shown). While HIV-1-infected MDM incubated in
medium alone inhibited CD40-dependent anti-T. gondii activity in
non-HIV-1 infected MDM, zidovudine-treated HIV-1-infected
MDM were unable to affect induction of anti-microbial activity
(Figure 1E). Taken together, HIV-1 impairs CD40-dependent
autophagic killing of T. gondii in primary macrophages not infected
with HIV-1.
Monocytic cells infected with HIV-1 block rapamycin-
induced autophagy in bystander cells
We further determined whether HIV-1 impairs autophagy in
bystander monocytic cells. Autophagy was assessed by examining
the distribution of the autophagy protein LC3. MonoMac6 cells (a
human monocytic cell line) transfected with LC3-eGFP were
incubated with cells infected with pseudotyped HIV-1 or
pseudotyped control virus and treated with or with out rapamycin,
a stimulator of autophagy, and examined for the development of
autophagosomes in LC3-eGFP
+ cells using fluorescent microscopy
(Figure 1F). MonoMac6 cells incubated with cells infected with
pseudotyped control virus exhibited large LC3
+ structures after
rapamycin treatment (Figure 1G). In contrast, incubation with
MonoMac6 cells infected with pseudotyped HIV-1 resulted in
reduced presence of autophagosomes in bystander cells after
rapamycin treatment as assessed by expression of large LC3
+
structures (Figure 1G, 1H). A decrease in autophagosomes could
be due to diminished autophagosome formation or increased
degradation. MonoMac6 cells were treated with bafilomycin A1,
an inhibitor of vacuolar ATPase, which prevents autophagosome
degradation [21]. MonoMac6 cells infected with pseudotyped
HIV-1 still inhibited the presence of autophagosomes in bystander
cells when autophagosome degradation was prevented (Figure
S1A). These results indicate that cells infected with HIV-1 inhibit
autophagosome formation in non-infected monocytic cells.
Macrophages/monocytic cells exhibit enhanced autophago-
some formation when they become infected with HIV-1 [17,18].
Incubation of the human monocytic cell line THP-1 with T cells
productively infected with HIV-1 results in HIV-1 infection of
THP-1 cells and autophagosome formation [17,18]. We used this
model to examine whether autophagy was still inhibited in
bystander monocytic cells when these cells were exposed to T cells
that produce infectious HIV-1. THP-1 cells were incubated with
pre-determined low concentrations of HIV-1-infected H9 T cells
that did not increase autophagy in THP-1 cells. Addition of
rapamycin caused a marked increase in autophagy in THP-1 cells
if they were incubated with uninfected H9 cells but not with HIV-
1-infected H9 T cells (Figure S1B). These results confirm that
autophagy is inhibited in primary macrophages and monocytic
cells exposed to cells infected with HIV-1.
HIV-1 Tat inhibits induction of autophagy
HIV-1 proteins can affect the function of cells not infected with
the virus. Given that cells infected with nef-, env-deficient HIV-1
inhibited autophagy in bystander cells, we determined whether
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PLoS ONE | www.plosone.org 2 July 2010 | Volume 5 | Issue 7 | e11733Figure 1. HIV-1 inhibits autophagy in bystander macrophages/monocytic cells. A and B, MDM from healthy controls and HIV-1
+ patients
were incubated with or without CD154 (3 mg/ml) (A) or IFN-c (200 U/ml) (B) followed by challenge with T. gondii tachyzoites. The number of parasites
per 100 macrophages was assessed by light microscopy 24 h post-challenge. HIV-1
+ patients were classified as non-responder when their
macrophages exhibited a percentage decrease in parasite load that was less than the 10
th percentile of the percentage decrease in parasite load
observed in macrophages from healthy controls. C–E, MDM from healthy controls were infected with pseudotyped HIV-1 (PV HIV) or pseudotyped
control virus (PV Ctr) and were incubated with a monolayer of uninfected macrophages. In certain experiments macrophages were treated with or
without zidovudine (AZT) 2 h after incubation with pseudotyped HIV-1 (E). Macrophage monolayers were treated with or without CD154 followed by
challenge with T. gondii and assessment of parasite load at 24 h. F, Schematic representation of MonoMac6 cells infected with pseudotyped HIV-1 (PV
HIV) or pseudotyped control virus (PV Ctr) incubated with uninfected MonoMac6 cells transfected with LC3-eGFP. Cells were treated with or without
rapamycin (1 mM) and assessed for autophagy by expression of large ($1 mm) LC3
+ structures. G, Flourescent images of LC3-eGFP
+ cells as treated in
panel (F). H, Quantification of autophagic cells as treated in panel (F). Data are representative of 4 independent experiments presented as means 6
SEM; ***p#0.001; **p#0.01; *#0.05; ‘p$0.05.
doi:10.1371/journal.pone.0011733.g001
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acid polypeptide that acts as the main transactivator of HIV-1. HIV-
1 Tat can be released from HIV-1-infected cells or dying cells
[22,23] and has been reported to exhibit pleiotropic extracellular
effects on uninfected bystander cells [24,25,26,27,28,29]. Mono-
Mac6 cells infected with pseudotyped HIV-1 were no longer able to
impair autophagy in LC3-eGPF
+ bystander MonoMac6 cells in the
presence of a neutralizing anti-Tat mAb (Figure 2A). Furthermore,
incubation of MonoMac6 cells with a low concentration of HIV-1
Tat inhibited rapamycin-induced autophagy as assessed by the
expression of large LC3
+ structures (Figure 2B). The effect of HIV-1
Tat was specific since it was ablated by a neutralizing anti-Tat mAb
(Figure 2B). In contrast, neutralization of TNF-a,a ni n d u c e ro f
autophagy, did not restore autophagy in HIV-1 Tat treated
macrophages (Figure 2B). The inhibition of autophagy by HIV-1
Tat was confirmed by examining the expression of LC3 isoforms.
The amount of LC3 II directly correlates with the level of autophagy
[2,30,31]. Immunoblot analysis of MDM treated with rapamycin
revealed that the addition of HIV-1 Tat reduced LC3 II expression
compared to controls (Figure 2C). HIV-1 Tat inhibited LC3 II
expression even in the presence of bafilomycin A1 (Figure 2D). This
supports previous experiments examining the presence of LC3
punctae in response to HIV-1 (Figure 1G, H; 2A, B), which indicate
that HIV-1 inhibits the induction of autophagy in bystander cells.
Next, the effect of HIV-1 Tat on autophagic killing of T. gondii
was examined. Figure 2E shows that low concentrations of HIV-1
Tat inhibited CD40-induced autophagic killing of T. gondii
whereas it had no effect on anti-T. gondii activity induced by
IFN-c (Figure 2F). We also examined the effects of a neutralizing
anti-Tat mAb on the autophagic killing of T. gondii. MDM infected
with pseudotyped HIV-1 were unable to inhibit anti-T. gondii
activity in response to CD40 stimulation when an anti-Tat mAb
was added to the culture (Figure 2G). Finally, we confirmed this
observation in MDM from HIV-1
+ patients whose cells were
refractory to CD40-induced killing of T. gondii. In the presence of
anti-Tat mAb, MDM from CD40 non-responders exhibited anti-
T. gondii activity similar to that of MDM from healthy controls
(Figure 2H). Taken together, HIV-1 Tat inhibited autophagy.
HIV-1 impairs autophagy in bystander macrophages/
monocytic cells through Src – Akt signaling
HIV-1 can activate Akt [32,33], which is an inhibitor of
autophagy [34,35]. To determine if Akt mediates the inhibitory
effects of Tat on autophagy, we initially examined if Tat induced
activation of Akt in macrophages. MDM exhibited enhanced
phosphorylation of Akt when incubated with HIV-1 Tat
(Figure 3A). Next, we determined if Akt signaling was necessary
for the inhibition of autophagy induced by HIV-1 Tat in
bystander cells. To this end, we silenced Akt in MonoMac6 cells
by utilizing siRNA (Figure 3B). Fluorescent microscopy of LC3-
eGFP
+ MonoMac6 cells revealed that HIV-1 Tat was unable to
inhibit autophagy when these cells were transfected with Akt1
siRNA (Figure 3C). Additionally, cells infected with pseudotyped
HIV-1 were no longer able to inhibit autophagy in MonoMac6
cells that had silenced Akt1 (Figure 3D). Similar results were
obtained with Akt inhibitor IV (Figure S2A). Incubation with Akt
inhibitor IV also ablated the ability of HIV-1 Tat to block CD40-
dependent autophagic killing of T. gondii (Figure 3E). These results
indicate that HIV-1 inhibits autophagy in bystander primary
macrophage and monocytic cells through an Akt-dependent
pathway.
To further investigate the manner in which HIV-1 modulates
autophagy in non-infected cells we examined signaling molecules
upstream of Akt. Phosphatase and tensin homologue (PTEN) is a
potent inhibitor of Akt signaling and it has been reported that
HIV-1 can reduce levels of PTEN [32]. However, we did not
detect reduction of PTEN expression in cultures of pseudotyped
HIV-1 infected cells or after macrophage treatment with HIV-1
Tat (Figure 4A). We then examined the phosphorylation state of
Src and FAK, classical activating kinases upstream of Akt [36].
MDM treated with HIV-1 Tat exhibited increased phosphoryla-
tion of Src and FAK (Figure 4B). Moreover, treatment of
macrophages with the Src inhibitor PP2 prior to addition of
HIV-1 Tat blocked Akt phosphorylation (Figure 4C), indicating
that activation of Src leads to Akt phosphorylation. Therefore, we
examined the role of Src in HIV-1-induced inhibition of
autophagy by utilizing siRNA (Figure 4D). Similar to the studies
with Akt, cells infected with pseudotyped HIV-1 were unable to
inhibit autophagy in MonoMac6 cells that had Src silenced by
siRNA (Figure 4E). These results were also reproduced in
MonoMac6 cells exposed to HIV-1 Tat (Figure S2B). Taken
together, these studies indicate that Src and Akt are required for
HIV-1-induced inhibition of autophagy in non-infected primary
macrophage and monocytic cells.
CXCR4, VEGFR1 and b-integrins are required for
inhibition of autophagy caused by HIV-1
Since HIV-1 Tat increased phosphorylation of Src and FAK in
macrophages, we examined the role of receptors known to signal
through these molecules: chemokine receptors, VEGFR and b-
integrin [37,38,39]. To this end, we blocked engagement of these
surface molecules on LC3-eGFP
+ MonoMac6 cells prior to
incubation with pseudotyped HIV-1 infected cells and treatment
with rapamycin. A blocking mAb against CXCR4 was used
because CXCR4 is a predominant chemokine receptor on
macrophages [40] and treatment of MonoMac6 cells with
recombinant SDF, the ligand for CXCR4, caused inhibition of
autophagy (Figure S3). VEGFR signaling was inhibited with a
mAb against VEGFR1 (the predominant form of VEGFR on
macrophages), or a VEGFR1 tyrosine-kinase inhibitor. b-integrin
signaling was inhibited with a blocking RGD peptide. Neutrali-
zation of any of these molecules impaired the ability of cells
infected with pseudotyped HIV-1 to inhibit autophagy in
bystander cells (Figure 5A). Similar results were obtained with
HIV-1 Tat (Figure 5B). These results suggest that all three cell
surface molecules are required for successful inhibition of
autophagy by HIV-1.
HIV-1 Tat has been reported to interact with chemokine
receptors, VEGFR, b-integrins and CD26 through the chemo-
kine-like domain, basic domain, RGD domain and CD26 binding
domain respectively [24,25,41,42,43]. To further confirm the role
of cell surface molecules in the inhibition of autophagy, we
assessed the ability of Tat with mutations in the above domains to
block rapamycin induced autophagy. To this end, we cultured
LC3-eGFP
+ MonoMac6 cells with cells transfected with a control
plasmid, a plasmid that encoded wild type HIV-1 Tat (Figure 5C),
or HIV-1 Tat with mutations at the CD26-binding, chemokine-
like (Tat31–101), basic or RGD domains. Equivalent expression of
each protein was corroborated by immunoblot using an anti-HA
antibody (not shown). Cells that expressed wild type HIV-1 Tat
inhibited autophagy in LC3-eGFP
+ MonoMac6 cells (Figure 5D).
Similar results were obtained with cells that expressed HIV-1 Tat
with deletion of the CD26 binding domain. In contrast, cells that
expressed HIV-1 Tat with mutations at the chemokine-like, basic,
or RGD domains lacked the ability to significantly inhibit
autophagy (Figure 5D). These results did not correlate with the
transactivation activity of HIV-1 Tat since wild type HIV-1 Tat,
and the RGD domain mutant exhibited transactivation activity
HIV-1 and Autophagy
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shown). Taken together, these results indicate that HIV-1 inhibits
autophagy in non-infected cells in a manner dependent on
chemokine, VEGFR and b-integrin signaling. Importantly,
inhibition of autophagy in bystander monocytic cells/macrophag-
es caused by HIV-1-infected cells and HIV-1 Tat exhibit similar
Figure 2. HIV-1 Tat inhibits autophagy. A, MonoMac6 cells infected with pseudotyped HIV-1 (PV HIV) or pseudotyped control virus (PV Ctr) were
incubated with uninfected MonoMac6 cells transfected with LC3-eGFP overnight in the presence or absence of either a neutralizing anti-Tat or
control IgG mAb. Cells were treated with or without rapamycin and assessed for autophagy by expression of large LC3
+ structures. B, MonoMac6 cells
transfected with LC3-eGFP were incubated overnight with HIV-1 Tat (100 pg/ml) plus either neutralizing anti-Tat, a neutralizing anti-TNF-a, or control
IgG mAb. Cells were then stimulated with rapamycin. Autophagy was assessed by examining expression of large LC3
+ structures. C, MDM were
treated with or without HIV-1 Tat followed by rapamycin. Cell lysates were obtained at 2 h and used for immunoblot for LC3 II and actin. D, MDM
were treated with or without HIV-1 Tat followed by rapamycin in the presence of bafilomycin A1 (Baf A1; 100 nM). Cell lysates were obtained at 2 h
and used for immunoblot for LC3 II and actin. E, and F, MDM were treated with increasing concentrations of HIV-1 Tat (E) or HIV-1 Tat (60 pg/ml) plus
IFN- c (100 U/ml) (F) with or without CD154. Macrophages were challenged with tachyzoites of T. gondii and assessed for parasite load at 24 h. G,
MDM infected with pseudotyped HIV-1 were incubated with uninfected macrophages. Cells were cultured in the presence of neutralizing anti-Tat or
control mAb. After stimulation with CD154, monolayers were challenged with T. gondii and parasite load was assessed at 24 h. H, MDM from CD40
non-responder HIV-1
+ patients were incubated with neutralizing anti-Tat or control mAb followed by stimulation with CD154. Macrophages were
challenged with T. gondii and assessed for parasite load at 24 h. Each symbol represents a different patient. The number of parasites per 100
macrophages was examined at 24 h by light microscopy. Data are representative of 3 to 4 independent experiments presented as means 6 SEM;
***p#0.001, ** p#0.01, ‘p$0.05.
doi:10.1371/journal.pone.0011733.g002
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VEGFR and b-integrin.
IL-10 and STAT3 are required for inhibition of autophagy
induced by HIV-1
Our data indicate that the presence of low percentages of cells
infected with HIV-1 or low concentrations of HIV-1 Tat were
sufficient to launch a robust inhibition of autophagy in bystander
macrophages/monocytic cells. We explored if HIV-1 utilizes an
additional pathway leading to an effective inhibition of autoph-
agy. HIV-1 and HIV-1 Tat upregulate IL-10 [44,45,46,47,48].
Indeed, we observed that MDM exhibited increased secretion of
IL-10 after exposure to 100 pg/ml of HIV-1 Tat (data not
shown). Thus, we explored IL-10 signaling as a possible
additional mechanism by which HIV-1 impairs autophagy.
Treatment of MonoMac6 cells with 100 pg/ml recombinant
human IL-10 impaired the induction of autophagy in response to
rapamycin (Figure 6A). Interestingly, however, the concentration
of IL-10 (30 pg/ml) detected after HIV-1 Tat treatment was
insufficient for inhibition of autophagy alone (data not shown).
Therefore, we determined whether cells infected with pseudo-
typed HIV-1 or HIV-1 Tat require the presence of IL-10 to
inhibit autophagy. In the presence of a neutralizing anti-IL-10
mAb, MonoMac6 cells infected with pseudotyped HIV-1 no
longer inhibited autophagy in rapamycin-treated non-infected
MonoMac6 cells (Figure 6B). Similarly, HIV-1 Tat was unable to
impair autophagy in rapamycin-treated MonoMac6 cells incu-
bated with anti-IL-10 mAb (Figure 6C).
Furthermore, IL-10 was also required for HIV-1-induced
inhibition of autophagic killing of T. gondii. MDM infected with
pseudotyped HIV-1 did not inhibit anti-T. gondii activity in
response to CD40 stimulation when an anti-IL-10 mAb was
present (Figure 6D). Finally, in the presence of anti-IL-10 mAb,
MDM from HIV-1
+ patients whose MDM were refractory to
CD40-induced autophagic killing of T. gondii, exhibited anti-T.
gondii activity similar to that of MDM from healthy controls
Figure 3. HIV-1 inhibits autophagy in bystander macrophages/monocytic cells through Akt. A, MDM incubated with or without HIV-1 Tat
(1 ng/ml) were examined for expression of total Akt and phospho-Akt by immunoblot. B, MonoMac6 cells were transfected with siRNA against Akt1 or
control siRNA. Expression of Akt and actin were examined 72 h post-transfection. C, MonoMac6 cells transfected with control or siRNA directed
against Akt1 were transfected with LC3-eGFP. Cells were incubated with or without HIV-1 Tat (100 pg/ml) overnight followed by stimulation with
rapamycin. Autophagy was assessed by examining expression of large LC3
+ structures. D, MonoMac6 cells were transfected with control siRNA or
siRNA directed against Akt. Cells were transfected with LC3-eGFP and incubated with MonoMac6 cells infected with pseudotyped control virus (PV
Ctr) or pseudotyped HIV-1 (PV HIV). Cultures were treated with or without rapamycin. Autophagy was assessed by examining expression of large LC3
+
structures. E, MDM were treated with Akt inhibitor IV (1.25 mM) or vehicle followed by incubation with HIV-1 Tat. Macrophages were incubated with
or without CD154, challenged with T. gondii and assessed for parasite load at 24 h. Data are representative of 3 independent experiments presented
as means 6 SEM; *p#0.05, **p#0.01, ‘p$0.05.
doi:10.1371/journal.pone.0011733.g003
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autophagy in bystander macrophages/monocytic cells.
STAT3 is a major signaling molecule downstream of IL-10
[49,50]. Thus, we examined the role of STAT3 in the inhibition of
autophagy induced by HIV-1 and IL-10. Transfection of
MonoMac6 cells with siRNA directed against STAT3 reduced
expression of this protein (Figure 7A). Silencing of STAT3
prevented IL-10 and HIV-1 Tat from inhibiting autophagy
induced by rapamycin (Figure 7B). The PI3K/Akt pathway has
also been reported to mediate IL-10 signaling [51,52,53]. Indeed,
silencing of Akt prevented IL-10 from inhibiting autophagy
induced by rapamycin (Figure 7B). Therefore, IL-10 signaling
through STAT3 and Akt is necessary for blockade of autophagy.
IL-10 appears unlikely to be the sole mediator of inhibition of
autophagy. In this regard, the concentration of IL-10 (30 pg/ml)
detected in MDM cultures after HIV-1 Tat treatment was
insufficient for blockade of rapamycin-induced autophagy (data
not shown). Moreover, IL-10 production induced by HIV-1 Tat is
reported to be independent of the basic and RGD domains while
these sites are required for inhibition of autophagy [54,55]. Taken
together, these results support a model whereby HIV-1 and IL-10
act in cooperation through Akt and STAT3 to impair autophagy
in bystander macrophage/monocytic cells (Figure 8).
Discussion
Microbial virulence factors have been reported to inhibit
autophagy by binding to Atg proteins [6,8,17]. Here we report
that a pathogen impairs autophagy by acting at upstream events in
the regulation of autophagy. HIV-1 inhibits autophagy in
bystander non-infected macrophages/monocytic cells. This inhi-
bition is dependent on Akt, its upstream activator Src as well as on
STAT3 and IL-10. The simultaneous signaling by Akt and
STAT3 contribute to the robust inhibition of autophagy induced
by HIV-1. We believe that data from this study provide a novel
insight into the strategies used by a pathogen to inhibit autophagy.
HIV-1 can affect a variety of signaling cascades. In this regard,
HIV-1 induces activation of Akt, Src and FAK [25,32,33,56]. Our
studies using gene knockdown and pharmacological inhibition of
Src and Akt identified them as mediators of HIV-1-induced
inhibition of autophagy in bystander macrophages/monocytic
cells. Moreover, b-integrins, chemokine receptors and growth
Figure 4. HIV-1 inhibits autophagy in bystander macrophages/monocytic cells through Src and Akt. A, MonoMac6 cells were cultured
with MonoMac6 cells infected with pseudotyped control virus (PV Ctr) or pseudotyped HIV-1 (PV HIV) or treated with HIV-1 Tat (100 pg/ml). Culture
lysates were examined by immunoblot for expression of PTEN and actin. B, MDM were incubated with or without HIV-1 Tat and examined for
expression of Src, phospho-Src, FAK and phospho-FAK by immunoblot. C, MDM were incubated with PP2 (20 mM) or vehicle followed by incubation
with HIV-1 Tat. Expression of total Akt and phospho-Akt were examined by immunoblot. D, MonoMac6 cells were transfected with control siRNA or
siRNA directed against Src and examined for expression of Src and actin. E, MonoMac6 cells transfected with control siRNA or siRNA directed against
Src were transfected with LC3-eGFP and incubated with pseudotyped control virus (PV Ctr) or pseudotyped HIV-1 (PV HIV)-infected MonoMac6 cells
overnight. Cultures were treated with or without rapamycin. Autophagy was assessed by examining expression of large LC3
+ structures. Data are
representative of 3 independent experiments presented as means 6 SEM; ***p#0.001, ‘p$0.05.
doi:10.1371/journal.pone.0011733.g004
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Akt [37,38,39]. Indeed, blockade of any of these surface molecules
impairs the ability of HIV-1 to inhibit autophagy in bystander
macrophage/monocytic cells. These findings suggest that signaling
through these receptors synergize to trigger inhibition of
autophagy.
HIV-1 infection results in dysregulation of IL-10. Cells exposed
to various HIV-1 proteins, including Tat, exhibit increased IL-10
production; furthermore, HIV-1
+ patients have increased serum
levels of IL-10 [44,45,47,48]. We identified IL-10 as an inhibitor
of autophagy and we report that HIV-1 also acts through IL-10 to
impair autophagy in bystander macrophage/monocytic cells. The
role of IL-10 is further supported by silencing of STAT3, a major
signaling molecule downstream of this cytokine. Relevant to these
findings is the report that telomere 39 overhang-specific DNA
oligonucleotides appear to induce autophagy by inhibiting STAT3
[57]. Thus, our studies indicate that inhibition of autophagy is part
of the constellation of inhibitory effects of IL-10 on macrophage
effector functions. IL-4 and IL-13 are cytokines that inhibit
autophagy through either Akt or STAT6 [58]. We report that IL-
10 impairs autophagy not only through STAT3 but also via Akt.
While our results support the existence of at least two pathways by
which HIV-1 inhibits autophagy in bystander macrophages, Src –
Akt and STAT3, the possibility of crosstalk between signaling
cascades cannot be ruled out. For example, there is evidence for
crosstalk and cooperation between STAT3 and Akt [59,60].
Additionally, not only IL-10 but also CXCR4 activates STAT3
[61]. Regardless of potential additional interactions between
Figure 5. HIV-1 inhibits autophagy in bystander macrophages/monocytic cells through CXCR4, VEGFR and b-integrin. A, MonoMa6
cells were transfected with LC3-eGFP and incubated with cells infected with pseudotyped control virus (PV Ctr) or pseudotyped HIV-1 (PV HIV).
Cultures were treated overnight with control mAb, control peptide cRAD, anti-CXCR4 mAb, anti-VEGFR1 mAb, VEGFR1 tyrosine kinase inhibitor, or b-
integrin blocking peptide cRGD. MonoMac6 cells were treated with or with out rapamycin and assessed for large LC3
+ structures. B, MonoMac6 cells
transfected with LC3-eGFP were treated overnight with or without Tat (100 pg/ml) and either control mAb, control peptide cRAD, anti-CXCR4 mAb,
anti-VEGFR1 mAb or b-integrin blocking peptide, cRGD. MonoMac6 cells were treated with or without rapamycin and assessed for large LC3
+
structures. C, Schematic representation of MonoMac6 cells transfected with LC3-eGFP cultured overnight with MonoMac6 cells transfected with a
control plasmid or a plasmid encoding Tat. Cultures were treated with rapamycin and assessed for large LC3
+ structures. D, MonoMac6 cells
transfected with LC3-eGFP were cultured overnight with MonoMac6 cells transfected with a control plasmid or a plasmid encoding either wild-type
Tat, Tat CD26 mutant, Tat chemokine-like domain mutant (Tat31–101), Tat basic domain mutant, or Tat RGD mutant as depicted in panel (C). Cultures
were treated with rapamycin and assessed for large LC3
+ structures. Data are representative of 4 independent experiments presented as means 6
SEM; *p#0.05, **p#0.01, ‘p$0.05.
doi:10.1371/journal.pone.0011733.g005
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are required for HIV-1-induced inhibition of autophagy in
bystander macrophages/monocytic cells.
Our work reveals that HIV-1-infected cells inhibit autophagy in
non-infected macrophages/monocytic cells. Various HIV-1 mol-
ecules affect the function of cells not infected with the virus. Our
studies with pseudotyped HIV-1 indicate that autophagy is
inhibited in bystander macrophages/monocytic cells despite the
lack of expression of Env and Nef. Moreover, blockade of
VEGFR, CXCR4 and b-integrin signaling restored autophagy.
This raised the possibility that HIV-1 Tat inhibits autophagy since
this molecule has sites with homology to natural ligands for those
receptors and HIV-1 Tat has been reported to exhibit pleiotropic
effects on uninfected bystander cells through interaction of HIV-1
Tat domains with VEGFR, chemokine receptors and b-integrins
[24,25,26,27,28,29]. However, the difficulty in measuring extra-
cellular HIV-1 Tat owing to the lack of suitable commercially
available reagents and the high concentrations of HIV-1 Tat used
in some studies have created controversy in the field. We report
that low concentrations of HIV-1 Tat inhibit autophagy in
macrophages/monocytic cells. The role of HIV-1 Tat as an
inhibitor of autophagy is further supported by the following
observations: i) Cells transfected with a tat-encoding plasmid
inhibit autophagy in bystander monocytic cells, ii) A neutralizing
anti-Tat mAb restores rapamycin-induced autophagy and CD40-
dependent autophagic killing of T. gondii in macrophages/
monocytic cells exposed to HIV-1-infected cells, iii) Neutralization
of HIV-1 Tat restores autophagic killing of T. gondii in
macrophages from HIV-1
+ patients. Importantly, the effects of
HIV-1 Tat on autophagy emulate the inhibition of autophagy in
bystander monocytic cells/macrophages caused by cells infected
with HIV-1, including reliance on host membrane receptors, Akt,
Src, and IL-10 signaling.
The effective inhibition of autophagy is likely explained by
cooperation between HIV-1 and upregulated IL-10. Modulation
of IL-10 by exogeneous HIV-1 Tat is reliant on amino acid
Figure 6. IL-10 is required for HIV-1 to inhibit autophagy in bystander macrophages/monocytic cells. A, MonoMac6 cells transfected
with LC3-eGFP were incubated with HIV-1 Tat (100 pg/ml) or IL-10 (100 pg/ml) overnight. Cells were then stimulated with rapamycin. Autophagy was
assessed by examining expression of large LC3
+ structures. B, MonoMac6 cells transfected with LC3-eGFP were incubated with MonoMac6 cells
infected with pseudotyped control virus (PV Ctr) or pseudotyped HIV-1 (PV HIV). Cultures were treated with either neutralizing anti-IL-10 or control
mAb overnight. Cells were then stimulated with rapamycin. Autophagy was assessed by examining expression of large LC3
+ structures. C, MonoMac6
cells transfected with LC3-eGFP were incubated with HIV-1 Tat (100 pg/ml) plus either neutralizing anti-IL-10 or control mAb overnight. Cells were
then stimulated with rapamycin. Autophagy was assessed by examining expression of large LC3
+ structures. D, MDM infected with pseudotyped HIV-
1 were incubated with uninfected MDM. Cells were cultured in the presence of either neutralizing anti-Tat, neutralizing anti-IL-10 or control mAb.
After stimulation with CD154, monolayers were challenged with T. gondii. The number of parasite per 100 macrophages was examined at 24 h by
light microscopy. E, MDM taken from a representative CD40 non-responder HIV-1
+ infected patient were cultured in the presence of neutralizing anti-
Tat, anti-IL-10 or control mAb. After stimulation with CD154, monolayers were challenged with T. gondii. The number of parasite per 100
macrophages was examined at 24 h by light microscopy. Data are representative of 3 independent experiments presented as means 6 SEM;
*p#0.05, **p#0.01, ***p#0.001, ‘p$0.05.
doi:10.1371/journal.pone.0011733.g006
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domain [54,55], however, not only the chemokine-like domain but
also the basic and RGD domain of HIV-1 Tat are required for
inhibition of autophagy. This is supported not only by studies
using inhibitors of VEGFR, b-integrin and CXCR4 signaling but
also by studies in which monocytic cells are exposed to cells that
express either wt tat or tat with mutations in the domains that
interact with these receptors. The synergistic signaling events
induced by Tat along with the presence of IL-10 provide an
effective inhibition of autophagy. Consistent with the notion that
IL-10 alone is insufficient for the inhibition of autophagy
prompted by HIV-1, IL-10 by itself does not block autophagy at
the concentrations detected in MDM cultures incubated with
HIV-1 Tat. Our results of IL-10 inhibition of autophagy support
the cooperation of Tat signaling. Therefore, HIV-1 and inducible
IL-10 likely function in combination to successfully inhibit
autophagy.
There is increasing evidence of the ability of HIV-1 to
manipulate autophagy. Env has been reported to induce
autophagy in bystander CD4
+ T cells through the fusogenic effect
of gp41 [62]. In contrast, Env was unable to induce autophagy in
bystander macrophages/monocytic cells [18]. HIV-1 plays a
complex role in modulation of autophagy within cells infected by
the virus. Autophagy is inhibited in CD4
+ T cells acutely infected
with HIV-1 [18,63]. In macrophages/monocytic cells infected
with HIV-1, while the early stages of autophagy are stimulated, the
degradative stage of this process is inhibited by Nef [17,18].
Although those studies provided an important insight into
modulation of autophagy within HIV-1-infected cells, the fact
that only a fraction of cells in vivo are estimated to be infected
stresses the importance of determining whether HIV-1 inhibits
autophagy in bystander cells. Little is known in this regard except
for the report that autophagy is inhibited in bystander neurons
treated with supernatants from microglia obtained from SIV-1
infected monkeys [19]. However, it was not determined if the
effect was a direct consequence of SIV-1. Indeed, it was postulated
that the bystander effect might be due to excitotoxic and pro-
inflammatory products secreted by microglia. We on the other
hand, demonstrate that HIV-1 is able to induce a robust inhibition
of autophagy in bystander macrophages/monocytic cells. This
phenomena may explain why macrophages from a subset of HIV-
1
+ patients exhibit defective CD40-dependent autophagic killing of
T. gondii. In this regard, macrophages from two CD40-non-
responder HIV-1
+ patients tested appeared to have detectable cells
with productive HIV-1 infection since approximately 0.5% of the
macrophages were p24
+ by flow cytometry (Andrade and
Subauste, unpublished observations). This supports that a small
proportion of HIV-1 infected cells can have a significant impact on
autophagy in HIV-1 non-infected cells.
Our findings are likely of relevance to various aspects of HIV-1-
induced disease. The role of autophagy as an immune effector
Figure 7. STAT3 and Akt are required for HIV-1 and IL-10 to inhibit autophagy. A, MonoMac6 cells were transfected with siRNA against
STAT3 or control siRNA. Expression of STAT3 and actin were examined 72 h post-transfection. B, MonoMac6 cells transfected with control siRNA or
siRNA directed against STAT3 or Akt were transfected with LC3-eGFP. Cells were incubated with or without HIV-1 Tat or IL-10 (both at 100 pg/ml)
overnight followed by stimulation with rapamycin. Autophagy was assessed by examining expression of large LC3
+ structures. Data are
representative of 3 independent experiments presented as means 6 SEM; ***p#0.001, ‘p$0.05.
doi:10.1371/journal.pone.0011733.g007
Figure 8. A schematic representation of the mechanism of HIV-
1-induced inhibition of autophagy. HIV-1 Tat interaction with the
cell surface receptors CXCR4, VEGFR, and b-Integrin induces signaling
through Src, it’s binding partner FAK, and Akt. Concomitant upregula-
tion of IL-10 by HIV-1 results in STAT3 activity, which functions in
cooperation with Akt to initiate a robust inhibition of autophagy.
doi:10.1371/journal.pone.0011733.g008
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pathogens, including M. tuberculosis, T. gondii, and Salmonella
typhimurium [4,11,64,65] suggests that the inhibition of autophagy
in bystander macrophages may contribute to the susceptibility of
HIV-1
+ patients to tuberculosis, toxoplasmosis and/or salmonel-
losis. The fact that autophagy can promote antigen presentation
[13,15] raises the possibility that inhibition of autophagy may
promote pathogen immune evasion. Autophagy is critical for
control of protein quality and prevention of neurodegenerative
diseases [66]. HIV-1 associated dementia (HAD) is becoming a
major problem in HIV-1
+ patients. It has been proposed that
dysregulation of autophagy by HIV-1 contributes to HAD [19].
The fact that patients with HAD exhibit perivascular infiltration
with HIV-1-infected monocytes [67] and the proposed link
between HIV-1 Tat and HAD [68] suggest that the mechanism
of autophagy inhibition reported here may contribute to the
development of HAD.
Studies in animal models of neurodegenerative disorders
revealed that pharmacologic manipulation of autophagy is of
therapeutic value [69,70]. The complex effects of HIV-1 on the
autophagy pathway suggest that therapeutic benefit may not be
easily achieved by generalized manipulation of autophagy through
targeting autophagy proteins. Our studies raise the possibility of a
more selective approach to manipulate autophagy by targeting
regulatory pathways. Since blockade of one signaling pathway (for
example VEGFR) remarkably diminishes the ability of HIV-1 to
impair autophagy in bystander cells, this mechanism may be more
easily exploited for therapeutic use in HIV-1
+ patients. Of note,
inhibitors of VEGFR, Src or Akt signaling are being explored for
cancer treatment [71,72,73].
In summary, we report that a pathogen inhibits autophagy by
modulating counter-regulatory signaling pathways, this inhibitory
effect can have global characteristics since it affects bystander (non
infected) macrophages/monocytic cells and approaches currently
developed for treatment of various disorders in humans prevent
inhibition of autophagy. The findings presented herein may be
relevant to the development of opportunistic infections, immune
evasion and neuro-degeneration in HIV-1
+ patients. These studies
may open up the possibility of novel treatments for complication of
HIV-1 infection based on the use of agents currently developed for
the management of other disorders in humans.
Materials and Methods
Ethics statement
Written informed consent was obtained from all subjects, and
the human experimentation guidelines of the US Department of
Health and Human Services were followed. The study was
approved by the Institutional Review Board of the University of
Cincinnati.
HIV-1
+ patients and control subjects
Blood samples were collected from 23 HIV-1 infected patients
followed at the Infectious Diseases Center of the University of
Cincinnati. Plasma viral load was measured by RT-PCR
(Amplicor, Roche). Blood samples were collected from 10 healthy
volunteers and used as control subjects.
Macrophage and monocytic cells
Human MDM were obtained as previously described [11,74],
MonoMac6 cells were a gift from Rene de Waal Malefyt (DNAX
Research Institute, Palo Alto, CA). Stable expression of LC3-
eGFP was achieved in THP-1 cells using a vector provided by
Christian Munz (University Hospital of Zurich, Switzerland). In
certain experiments, macrophages and monocytic cells were
treated with varying concentrations of recombinant Tat1–101
(Tecnogen), recombinant human IL-10 (100 pg/ml; PeproTech),
recombinant IFN-c (200 U/ml; PeproTech), neutralizing mAb
against either Tat (10 mg/ml; Immunodiagnostics), IL-10 (10 mg/
ml; BD Biosciences), TNF-a (10 mg/ml; Endogen), CXCR4
(25 mg/ml; R&D Systems), VEGFR1 (10 mg/ml; R&D Systems),
control mouse IgG (BD Biosciences), goat IgG (Jackson Immu-
noResearch Laboratories, Inc.), Akt inhibitor IV (1.25 mM;
Calbiochem), integrin blocking peptide cRGDfV (3 mM; Bachem)
or control peptide cRADfV (3 mM; Bachem).
T. gondii infection
MDM were stimulated with CD154 (3 mg/ml; Amgen) for 72 h
in the presence of macrophages infected with pseudotyped HIV-1
(see below), recombinant HIV-1 Tat (60 pg/ml added daily for 3
days unless otherwise stated) and/or Akt inhibitor (1.25 mM).
Tachyzoites of the RH strain of T. gondii were maintained in
human foreskin fibroblasts and were used to infect human MDM
[11,74]. Monolayers of macrophages were examined by light
microscopy after 24 h to assess parasite load as described
[11,74,75]. Changes in the number of T. gondii infected cells were
not due to differences in cell detachment during processing of
samples or HIV-1 presence. In addition, cell densities as
determined with an eyepiece grid were similar in all experimental
groups.
Pseudotyped HIV-1 infection
To generate pseudotyped HIV-1, we co-transfected 293T cells
with VSV-G, pMDL-g/p RRE and either pNL4-3.HSA.E
2
(obtained from Dr. Nathaniel Landau through the AIDS Research
and Reference Reagent Program) or HIV-1 transfer plasmid pHR’
as control. pNL4-3.HSA.E
2 contains a construct for the murine
Heat Stable Antigen (HSA, CD24) fused in frame to the nef
initiator methionine codon. The env gene is not expressed due to a
59 frameshift. Thus, viral particles formed after initial infection
with VSV-G pseudotyped HIV-1 lack HIV-1 gp160 and are
unable to infect other cells. pHR’ contains viral LTR and does not
express any HIV-1 proteins. Supernatants were collected at 24 and
48 h, passed through a 0.45 mm filter, concentrated by ultracen-
trifugation and stored at 280uC. MDM and MonoMac6 cells
(1610
6 cells/well in 24-well plates) were infected with pseudotyped
HIV-1 as described in the presence of polybrene (8 mg/ml; Sigma)
in a final volume of 250 ml for 2 h [76]. In certain experiments
zidovudine (10 mM, Sigma Chemical) was added 2 h after
incubation with HIV-1. Percentages of infected cells were assessed
at 48 h by examining expression of cell surface mouse HSA or
intracellular p24 by flow cytometry.
Assessment of Autophagy
MonoMac6 cells were transfected with LC3-eGFP or double
transfected with LC3-eGFP and siRNA for Akt1, Src, or STAT3
by Amaxa Nucleofection (Amaxa) per manufacturer’s protocol.
The percentage of LC3-eGFP transfected MonoMac6 cells was
consistent amongst all groups. Cells were plated in an 8-well
chamber slide and treated with recombinant HIV-1-Tat (100 pg/
ml) for 16 hours, then incubated with rapamycin (1 mM;
Calbiochem) for 2 h to stimulate autophagy. At least 200 LC3-
eGFP
+ MonoMac6 cells were counted to examine the presence of
large ($1 mm) LC3
+ structures using a Leica fluorescent inverted
microscope at 4006 magnification. In additional experiments,
MonoMac6 cells were infected with pseudotyped HIV-1, or
transfected with either wild-type Tat101 plasmid or mutant
plasmids. After 48 h these cells were incubated for 16 h with
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Autophagy was assessed as described above 2 h after addition of
rapamycin. In certain experiments, cultures were treated with
bafilomycin A1 (100 nM; Sigma Chemical) for 2 h prior to
autophagy assessment. In additional experiments, uninfected H9
T cells or H9/HTLV-III T cells (gift from David Canaday) were
incubated for 72 h with THP-1 cells that express LC3-eGFP.
Autophagy was assessed as described above 2 h after addition of
rapamycin. In addition, immunoblot analysis was utilized to
determine autophagy induction by expression of LC3 II. MDM or
MonoMac6 cells stimulated with HIV-1 Tat with or without
rapamycin and bafilomycin A1 were lysed and analyzed by
immunoblot, as described below, for expression level of LC3 II.
Transfection of monocytic cells
MonoMac6 cells were transiently transfected with plasmids
encoding LC3-eGFP (gift from T. Yoshimori National Institute for
Basic Biology, Okazaki, Japan); Tat1–101 or the Tat mutants described
below using an Amaxa Nucleofector per manufacturer’s instructions
[11]. Knockdown of Akt1, Src and STAT3 were performed by
transfecting MonoMac6 cells with previously described siRNA
duplexes [77,78,79] (Dharmacon Inc.) using an Amaxa Nucleofector.
Control siRNA from Dharmacon Inc. was used as control. After 48 h,
MonoMac6 cells were transfected with LC3-eGFP.
Plasmids
A construct of recombinant hemagglutinin (HA)-tagged wild-
type Tat (Tat1–101); Tat31–101 was subcloned into the plasmid
pLINK2 using EcoRV and SpeI enzymes. Constructs that encode
mutants of Tat were generated by PCR based mutagenesis. Site
directed mutagenesis was carried out with QuickChange XL Site-
Directed Mutagenesis Kit (Stratagene) following manufacturers
instructions. The following oligonucleotides were used to generate
mutants: RGD mutant (TatR(78)K,D(80)E)5 9-CCC GCC TCC CAG
TCC AAA GGG GAA CCG ACA GGG CCC-39; basic mutant
(TatR(53,54,55,56,58,59)A)5 9- GGC ATC TCC TAT GGC GCG
AAG AAG GCG GCA CAG GCA GCA GCA GCT CCT CAG
GAC -39; CD26 binding domain mutant (Tat21–101)5 9-GGG
GAA TTC CCC TGG AAG CAT CCA GGA AGT CAG CC-39.
Resulting mutants were confirmed by sequencing (Integrated
Biotechnologies).
Immunoblotting
Primary macrophages or MonoMac6 cells treated with
recombinant Tat were lysed and assessed for expression of various
signaling proteins. In brief, cytoplasmic protein was separated
using Tris-HCL gels (BioRad) and transferred to PVDF
membranes for probing overnight with primary antibodies
directed against Akt, phospho-Akt, Src, phospho-Src, PTEN (all
from Cell Signaling Technologies), FAK (Santa Cruz Biotechonol-
ogies), phospho-FAK (BD Bioscience), LC3 (MBL Technologies)
and HA (Cell Signaling Technologies). The membranes were
incubated with corresponding secondary antibodies and the signal
was visualized by using a chemilluminescent kit (Pierce Biosci-
ence). In addition, MonoMac6 cells were lysed 72 h after
transfection with siRNA for Akt1, Src, or STAT3 and probed
with antibodies against Akt, Src, STAT3 (R & D Systems) and
Actin (Santa Cruz Biotechnologies) to ensure proper knockdown.
Flow cytometry
Human MDM and MonoMac6 cells were incubated with
human IgG (20 mg/ml) for 15 min followed by incubation with
anti-CD40, anti-HSA or isotype control mAb (Pharmingen). Cells
were fixed with 1% paraformaldehyde and analyzed using an LSR
II (BD Biosciences). For detection of intracellular p24, cells were
fixed and permeabilized using IntraPrep permeabilization reagent
(Beckman Coulter). Thereafter, cells were stained with anti-p24 or
isotype control mAb (Beckman Coulter). After fixation with 1%
paraformaldehyde, cells were analyzed using an LSRII.
Statistics
Statistical significance was assessed by 2-tailed Student’s t test
and ANOVA. Values less than 0.05 were considered statistically
significant. Linear-regression analysis was performed to determine
the relationship between CD40-induced anti-T. gondii activity,
CD4 counts and viral load.
Supporting Information
Figure S1 HIV-1 inhibits autophagy in bystander cells. A,
MonoMac6 cells infected with pseudotyped HIV-1 (PV HIV) or
pseudotyped control virus (PV Ctr) were incubated with
uninfected MonoMac6 cells transfected with LC3-eGFP. Cells
were treated with or without rapamycin (1 mM) in the presence of
bafilomycin A1 (BafA1; 100 nM) and assessed for autophagy by
expression of large LC3+ structures. B, THP-1 cells that express
LC3-eGFP were incubated for 72 h with either HIV-1-infected or
uninfected H9 T cells. Cultures were treated with rapamycin.
Autophagy was assessed by examining expression of large LC3+
structures. Data are representative of 2 independent experiments
presented as means + SEM; **p,0.01, ***p,0.001, ‘p.0.05.
Found at: doi:10.1371/journal.pone.0011733.s001 (0.36 MB TIF)
Figure S2 HIV-1 Tat inhibits autophagy in an Akt-Src-
dependent manner. A, MonoMac6 cells transfected with LC3-
eGFP were incubated overnight with or with out HIV-1 Tat
(100 pg/ml) in the presence of Akt inhibitor (1.25 mM). Cells were
then stimulated with rapamycin. Autophagy was assessed by
examining expression of large LC3+ structures. B, MonoMac6
cells transfected with control siRNA or siRNA directed against Src
were transfected with LC3-eGFP and treated with HIV-1 Tat
overnight. Cultures were treated with or without rapamycin.
Autophagy was assessed by examining expression of large LC3+
structures. Data are representative of 3 independent experiments
presented as means + SEM; **p,0.01, ‘p.0.05.
Found at: doi:10.1371/journal.pone.0011733.s002 (0.33 MB TIF)
Figure S3 CXCR4 activation inhibits autophagy. MonoMac6
cells transfected with LC3-eGFP were incubated overnight with
SDF-1 (100 pg/ml). Cells were then stimulated with or with out
rapamycin. Autophagy was assessed by examining expression of
large LC3+ structures. Data are representative of 3 independent
experiments presented as means + SEM; **p,0.01.
Found at: doi:10.1371/journal.pone.0011733.s003 (0.22 MB TIF)
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